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Importance of knowing what drugs the patient has taken in the referral pathway for
suspected cancer.
Boyes H, Kanatas A.
Dear Editor,
In 2014, there were 7026 new cases of oral cancer in England
1
. In 2015, NICE updated its
guidance on referral pathways for suspected oral cancer
2
. It broke down its criteria into the
following:
 Suspected cancer referral pathway (non-dentist referrer)
o Unexplained ulceration > 3 weeks
o Persistent and unexplained lump in the neck
 Urgent referral (for assessment for oral cancer by a dentist) or Suspected cancer
referral pathway (dentist referrer)
o Lump in the lip or oral cavity consistent with oral cancer
o A red or red and white patch consistent with erythroplakia
o Erythroleukoplakia
The result of these referrals to OMFS or Oral Medicine clinics usually comprise a detailed
patient history, clinical imaging, and the decision to biopsy the lesion or monitor as
appropriate.
A potentially overlooked aspect of the referral system is drug history. Many medications can
result in an altered oral appearance, for example, gingival hyperplasia due to sodium
valproate
3
. However, there has been recent evidence to suggest that antihypertensive
medications may be associated with an increased risk of SCC of the lip.
Several antihypertensive medications, including Nifedipine, Lisinopril, and particularly
Hydrochlorothiazide, have a side effect of photosensitivity. Studies have shown that this




Antihypertensive medications are common drugs that are likely to be prescribed to patients
who have other carcinogenic risk factors (i.e. smokers and drinkers). Therefore, an important
aspect of the referral and management process for suspected cancer should include a
thorough drug history, as it could be increasingly influential in the decision to biopsy or to
monitor.
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